key: cord-0077550-gtg8w4y1
authors: Panizo, Nayara; Albert, Eliseo; Giménez-Civera, Elena; Puchades, Maria Jesús; D'Marco, Luis; Gandía-Salmerón, Lorena; Giménez, Estela; Torre, Ignacio; Sancho, Asunción; Gavela, Eva; Gonzalez-Rico, Miguel; Montomoli, Marco; Perez-Baylach, Carmen Maria; Bonilla, Begoña; Solano, Camila; Alvarado, Mª Fernanda; Torregrosa, Isidro; Alcaraz, María Jesús; Górriz, José Luis; Navarro, David
title: Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within three months after COVID-19 full vaccination
date: 2022-04-09
journal: Clin Kidney J
DOI: 10.1093/ckj/sfac093
sha: c64ff8cde30d251f556dc50fda1ca3011e032a07
doc_id: 77550
cord_uid: gtg8w4y1

BACKGROUND: Little is known regarding the dynamics of antibody and T-cell responses in chronic kidney disease (CKD) following COVID-19 vaccination. MATERIAL AND METHODS: Prospective observational cohort study including 144 participants on hemodialysis (HD) (n = 52), peritoneal dialysis (PD) (n = 14), kidney transplantation (KT) (n = 30) or advanced chronic kidney disease not on dialysis (ACKD), and healthy controls (n = 18). Anti-Spike(S) antibody and T-cell responses were assessed at 15 days (15D) and 3 months (3M) after complete vaccination schedule. HD, PD and KT patients received mRNA vaccines (mRNA-123 and BNT162b2). Most ACKD patients received BNT162b2 (n = 23), or Ad26.COV.2.S (4). Most controls received BNT162b2 (n = 12), or Ad26.COV.2.S (n = 5). RESULTS: Anti-S antibodies at 15D and 3M were detectable in 95% (48/50)/98% (49/50) of HD patients, 93% (13/14)/100% of PD patients, 67% (17/26)/75% (21/28) of KT patients and 96% (25/26)/100% (24/24) of ACKD patients. Rates for healthy controls were 81% (13/16)/100% (17/17). Previous SARS-CoV-2-S infection was documented in 4 (7,7%) HD patients, 2 (14,3%) PD patients, 2 (6,7%) KT patients, 1 (5,55%) healthy controls and in no ACKD patient. Antibody levels decreased at 3M in HD (p = 0.04), PD (p = 0.008), and ACKD patients (P = 0.0009). In KT patients levels increased (P = 0.04) between 15D and 3M, although they were low at both time points. T-cell responses were detected in HD patients in 37 (80%) at baseline, 35 (70%) at 15 days and 41 (91%) at 3 months. In PD patients, T-cell responses appeared in 8 (67%) at baseline, 13 (93%) at 15 days and 9 (100%) at 3 months. In KT patients, T-cell responses were detected in 12 (41%) at baseline, 22 (84%) at 15 days and 25 (96%) at 3 months.In ACKD patients, T-cell responses were detected in 13 (46%) at baseline, 20 (80%) at 15 days and 17 (89%) at 3 months. None of healthy controls showed T-cell response at baseline, 10 (67%) at 15 days and 8 (89%) at 3 months. CONCLUSIONS: Most HD, PD and ACKD patients develop SARS-CoV-2-S antibody responses comparable to that of healthy controls, in contrast to KT recipients. Antibody waning at 3M was faster in HD, PD, ACKD patients. No differences in SARS-CoV-2 T-cell immunity responses were noticed across study groups.

first WHO COVID-19 antibody standard 36 and a whole-blood flow cytometry assay for intracellular cytokine staining for enumeration of S-reactive T cells 37 were used for this purpose.

We conducted a prospective, observational cohort study between March and October, 

The data underlying this article will be shared on reasonable request to the corresponding author. Overall, antibody levels measured at 15D were found to decrease at 3M (P=0.04) ( Figure 1 and Table 2 ) by a median of 2.5 fold (range, 0.08-16.4). Antibody decline was comparable (P=0.49) for patients vaccinated with mRNA1273 (median, 2.28-fold) and ( Figure 3 ). Baseline SARS-CoV-2-S T-cell responses were documented in 67% (8/12) of patients (Table 3 ). The rate of detectable responses increased by 15D (13/14; 93%) and 3M after vaccination (9/9; 100%), with no differences across patients vaccinated with mRNA1273 and BNT162b2 (not shown). In addition, overall, the frequencies of both

SARS-CoV-2-S CD8 + and CD4 + T cells were not significantly different (P=0.6) at baseline and 3M (Table 3) , irrespective of the vaccine platform used (not shown). Table 2 ). Antibody levels increased (P=0.04) between 15D and 3M, although they were rather low at both time points (median of 5 and 58 BAU/ml, respectively; Table 2 ).

Detectable SARS-CoV-2-S T-cell responses were present in 41% (12/27), 84% (22/26) and 96% (25/26) of patients at baseline, at 15D and 3M after full vaccination ( Table 3) .

Frequencies of both SARS-CoV-2-S CD8 + and CD4 + T cells were found to increase at 3M compared to baseline levels (P=0.08 and P=0.01, respectively). 

measured at 15D. SARS-CoV-2-S T cells were detected in 46% of patients (13/28) at baseline and the rate of detection increased afterwards reaching 80% (20/25) and 89%

(17/19) of patients at 15D and 3M, respectively. As shown in Table 3 , the frequency of both SARS-CoV-2 S-CD4 + and CD8 + T cells increased at 15D (P=0.10 and P=0.03, respectively) as compared to that found at baseline and remained relatively stable at 3M (P=0.95 and P=0.60, respectively).

Controls (n=18; 13 female; median, 68.5 years; range 29-77) had been vaccinated with BNT162b2 (n=11), Janssen Ad26.CoV2.S vaccine (n=6) or mRNA1273 (n=1). All, but one patient were SARS-CoV-2 naïve prior to vaccination. Detectable anti-RBD antibodies antibodies were found in 81% (13/16) and 100% (17/17) by 15D and 3M

after full vaccination, respectively. Antibody levels waned slightly at 3M (Table 2 and 67% (10/15) and 89% (8/9) exhibited them at 15D and 3M, respectively (Table 3) .

SARS-CoV-2-S CD4 + and CD8 + T-cell frequencies were found to increase, albeit not significantly (P=0.38 and P=0.080, respectively) between 15D and 3M (Supplementary Figure 4) .

Due to the limited study sample size, a comparative analysis of the kinetics of SARS-CoV-2-S antibody and T-cell responses following vaccination with mRNA1273 could only be performed for dialysis and KT patients (Table 4 ). Significant differences were observed across groups regarding both the rate of detection and measurable levels of

anti-RBD total antibodies, which were lower in KT as compared to dialysis patients, regardless of whether or not SARS-CoV-2 experienced individuals were included in the analyses (supplementary Table 1 ). In addition, while the rate of detection and median frequency of SARS-CoV-2-S CD4 + T cells appeared comparable across groups, that of SARS-CoV-2-S CD8 + T cells were substantially higher in PD as compared to HD and KT. SARS-CoV-2-S antibody and T-cell responses in HD, ACKD and controls after vaccination with BNT162b2 could also be compared. Notably, we found no significant differences across groups.

We examined SARS-CoV-2-S-reactive antibody and T-cell responses in CKD patients, including HD, PD, ACKD, KT and healthy controls early (15D) and at mid-term (3M)

following full vaccination with different COVID-19 vaccine platforms, mainly mRNA1273 and BNT162b2. To our knowledge this is the first study to analyse T cell response in CKD at three months. To that purpose we used a SARS-CoV-2-RBD total antibody assay calibrated to the first WHO SARS-CoV-2 antibody standard, 36 returning quantitative results that strongly correlate with neutralizing antibody titers measured using wild-type virus neutralization assays. 38,39 In turn, we employed a whole-blood flow cytometry assay for enumerating peripheral blood SARS-CoV-2-S-reactive CD4 + and CD8 + T cells. 37 It is important to stress that the comparison of immunological data from this study with that reported in other studies, using SARS-CoV-2-S1 or S trimeric chemiluminescent antibody assays or ELISPOT/Quantiferon® assays for assessment of T-cell responses, is not straightforward. There are notable differences in the analytical features of each data set. Also, there is a lack of side-by-side performance comparison studies carried out in the above or other population groups. In addition, when comparing the findings of the current study with those of others studies it is important to note that In our study, the overall prevalence of vaccinated individuals displaying SARS-CoV-2-S T cell responses at 15D was rather high (between 67-93%) and similar in participants across all groups. Moreover, detectable T-cell responses were documented at 3M for the majority of participants with no substantial differences noted across HD, PD, ACKD or KT patients and healthy controls, neither in terms of prevalence nor magnitude. For participants vaccinated with mRNA1273, however, those undergoing PD appeared to display a higher rate of detectable T-cell responses at 3M than did HD and KT patients.

Beyond detection rates, the magnitude of T-cell responses has been consistently reported to be lower in dialysis, ACKD and KT patients relative to that of healthy 

Factors associated with COVID-19-related death using OpenSAFELY

The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review

Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD

3M, median of 15 days and three months after completion of the vaccination schedule; ACKD, Advanced chronic kidney disease

The authors declare no conflicts of interest. weeks anti-S1-RBD IgG